The phase I/II clinical trial (NCT03001310) tested the safety and efficacy of AAV8-hCARp.hCNGB3 gene replacement therapy on 23 participants (11 adults and 12 children) with CNGB3-associated achromatopsia [14]. This evidence concerns the gene CNGB3 and achromatopsia.